Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeff Ubben is Bullish on Allison Transmission Holdings Inc (ALSN) and There Are Reasons Why

Jeff Ubben is bullish on Allison Transmission Holdings Inc (NYSE:ALSN) and recently his fund, ValueAct Partners, boosted its position in the company. As a new filing with the Securities and Exchange Commission showed, ValueAct acquired a total of 550,000 shares of Allison Transmission, raising its position to around 18.58 million shares. The shares have been acquired in eight transactions, the average price amounting to $28.31 per unit. Following the increase, ValueAct owns 10.5% of Allison Transmission’s common stock.


ValueAct has not disclosed the nature of the stake, although it’s most likely a passive position, since ValueAct has been holding a significant stake in Allison for over a year and has not revealed any activist moves regarding the company. And so far, Allison Transmission Holdings Inc (NYSE:ALSN) has been performing pretty well.

The company produces and sells commercial and military fully-automatic transmissions. With the auto parts industry growing, Allison has also showed a solid performance, with its stock gaining around 3.7% since the beginning of the year, versus the industry return of around 9%, and outrunning most of its peers in the industry.

On the financial side, Allison Transmission Holdings Inc (NYSE:ALSN) has also been reporting a good performance, with  its revenue, EBITDA and net income posting single digits growth over the last several quarters. For the second quarter of 2013, the revenue amounted to approximatelly $535 million, up by 4% on the year, while its EBITDA and EPS grew to $180 million and $0.31 respectively, from $165 million and $0.26 a year ago. Analysts expect further growth during this year, with the EPS consensus standing at around $2.35, versus reported $1.85 a year ago.

Among the midcap auto parts companies, Allison Transmission Holdings Inc (NYSE:ALSN) is priced cheaper in comparison to some other peers, such as Visteon Corp (NYSE:VC), or Lear Corporation (NYSE:LEA), which, however, returned around 20% and 11% year-to-date. Moreover, it trails a P/E of 26.80, which is one of the highest among its peers, and is significantly above the industry average of 18.60.

Earlier in September, Zacks upgraded Allison Transmission Holdings Inc (NYSE:ALSN)’s rating to ‘Outperform’ from ‘Neutral’ and setting a target price of $32.70, which represents a significant premium on $28.50, the current price of the stock.

Among the investors of Allison Transmission Holdings Inc (NYSE:ALSN) that we track at Insider Monkey, the vast majority boosted their exposure to the company. For example, David E. Shaw increased his stake by 27% during the second quarter and owns 9.66 million shares as of the end of June. Lee Ainslie of Maverick Capital placed a big bet on Allison during the same period, opening a position that contains 6.37 million shares and amasses 2.84% of Maverick’s equity portfolio.

Nevertheless, despite the fact that ValueAct has not gone activist on Allison, there is a reason to believe that it might soon do so, since it would be in line with its strategy. Jeff Ubben prefers to amass significant positions in companies that he considers to be undervalued and then discusses with the board offering long-term growth strategies. Given that ValueAct has been one of the best performing hedge funds for several years (last year returned over 29%), it’s bet on Allison seems to be more interesting that it looks at the first sight.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!